Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01039376
First received: December 23, 2009
Last updated: April 2, 2015
Last verified: April 2015
  Purpose

The purpose of this study is to determine if maintenance therapy with ofatumumab will prolong remission in patients with CLL who have responded to second or third line treatment. This study will also evaluate the safety of ofatumumab maintenance compared to observation (the current standard of care). This study was co-developed with the HOVON and NORDIC CLL group and will be conducted as a collaborative effort with GSK.


Condition Intervention Phase
Leukaemia, Lymphocytic, Chronic
Biological: Ofatumumab
Other: Observation
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase III, Open Label, Randomized, Multicenter Trial of Ofatumumab Maintenance Treatment Versus no Further Treatment in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) Who Have Responded to Induction Therapy

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Progression-free Survival, as Assessed by the Investigator [ Time Frame: From randomization until progression or death (up to 84 months) ] [ Designated as safety issue: No ]
    Progression-free survival is defined as the time from randomization to the date of disease progression (PD) or death due to any cause. PD was determined by the investigator according to the definitions of response in the International Workshop for Chronic Lymphocytic Leukemia (IWCLL) updated National Cancer Institute-Sponsored Working Group (NCI-WG) guidelines. According to the guidelines, PD is characterized by at least one of the following: lymphadenopathy (appearance of any new lesion such as enlarged lymph nodes (>1.5 centimeter [cm]), spleen or liver or other infiltrates or an increase by 50% or more in the greatest diameter of any previous site); an increase by 50% or more in the previously noted enlargement of the liver or spleen; an increase by 50% or more in the numbers of blood lymphocytes with at least 5000 lymphocytes per microliter; transformation to a more aggressive histology, or occurrence of cytopenia attributable to chronic lymphocytic leukemia.

  • Progression-free Survival, as Assessed by the Independent Review Committee (IRC) [ Time Frame: From randomization until progression or death (up to 84 months) ] [ Designated as safety issue: No ]
    Progression-free survival is defined as the time from randomization to the date of disease progression (PD) or death due to any cause. PD was determined by the IRC according to the definitions of response in the International Workshop for Chronic Lymphocytic Leukemia (IWCLL) updated National Cancer Institute-Sponsored Working Group (NCI-WG) guidelines. According to the guidelines, PD is characterized by at least one of the following: lymphadenopathy (appearance of any new lesion such as enlarged lymph nodes (>1.5 centimeter [cm]), spleen or liver or other infiltrates or an increase by 50% or more in the greatest diameter of any previous site); an increase by 50% or more in the previously noted enlargement of the liver or spleen; an increase by 50% or more in the numbers of blood lymphocytes with at least 5000 lymphocytes per microliter; transformation to a more aggressive histology, or occurrence of cytopenia attributable to chronic lymphocytic leukemia.


Secondary Outcome Measures:
  • Overall Survival [ Time Frame: From randomization until death (up to 84 months) ] [ Designated as safety issue: No ]
    Overall survival is defined as time from randomization to date of death.

  • Number of Participants With Improvement in Response From Baseline [ Time Frame: From Baseline until the end of the study (up to 24 months) ] [ Designated as safety issue: No ]
    Improvement in response was assessed by calculating the percentage of participants who changed from partial response (PR) at Baseline to complete response during the study.

  • Time to Next Therapy [ Time Frame: From randomization until the end of the study (up to 84 months) ] [ Designated as safety issue: No ]
    Time to next therapy is defined as the time from randomization to the date of receiving the next CLL treatment.

  • Progression-free Survival After Next-line Therapy [ Time Frame: From randomization until progression or death (up to 84 months) ] [ Designated as safety issue: No ]
    Progression-free survival after next-line therapy is defined as the time from randomization until progression or death following the next-line therapy and counted as events deaths prior to next-line therapy. Participants who received next-line therapy and who did not have progression or death after next-line therapy were censored at their last date of contact. Participant who died prior to next-line therapy, was counted as an event.

  • Time to Progression After Next-line Therapy [ Time Frame: From randomization until progression or death (up to 84 months) ] [ Designated as safety issue: No ]
    Time to progression after next-line therapy is defined as the time from progression following randomization until progression or death following next-line therapy and counted as events deaths prior to next-line therapy. Participants who received next-line therapy with a PD prior to receiving next line therapy and who did not had progression or death after next-line therapy were censored at their last date of contact. If a participant died prior to next-line therapy, this was counted as an event.

  • Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, Chronic Lymphocytic Leukaemia 16 Item Module (EORTC QLQ-CLL 16) [ Time Frame: From randomization until the end of the study (up to 84 months) ] [ Designated as safety issue: No ]
    The EORTC QLQ-CLL16 is comprised of 16 questions that address 5 domains of health-related quality of life (HRQoL) important in CLL. There are 4 multi-item scales - fatigue (2 items), treatment side effects ([TSE], 4 items), disease symptoms (disease effects scale [DES], 4 items), and infection (4 items) - and single item scales (social activities [Social Problems (SP) Scale] and future health worries [Future Health (FH) Scale]). These are measured on a four point Likert scale where 1 = not at all and 4 = very much. These scores are transformed to give a rating from 0 - 100, where 0 =no symptoms or problems and 100 = a severe symptoms or problems. Changes from Baseline were analyzed by mixed model-repeated measures analysis of covariance (ANCOVA).

  • Change From Baseline in the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Score [ Time Frame: From randomization until the end of the study (up to 84 months) ] [ Designated as safety issue: No ]
    The EORTC QLQ-C30 is a self-reported, 30-item cancer-specific instrument that assesses 15 domains: physical functioning (5 items), role functioning (2 items), emotional functioning (4 items), cognitive functioning (2 items), social functioning (2 items), pain (2 items), fatigue (3 items), nausea and vomiting (2 items), five single item symptom scores (insomnia, loss of appetite, constipation, diarrhea, and dyspnea), a single item asking about financial difficulties and a global health status/quality of life (QOF) consisting of 2 items. Functional and symptoms scales were measured on a four point Likert scale where 1 = not at all and 4 = very much, whereas global health status or QOF was assessed using a 7-item Likert scale, ranging from "poor" to "excellent". Changes from Baseline were analyzed by mixed model-repeated measures ANCOVA.

  • Change From Baseline in the Quality of Life Status as Assessed by the EuroQol-5D (EQ-5D) Scale [ Time Frame: From randomization until the end of the study (up to 84 months) ] [ Designated as safety issue: No ]
    EQ-5D is comprised of a 5-item health status measure and a visual analogue scale (VAS) and is used to generate two scores: the utility score and the thermometer score. The utility score measures mobility, self-care, usual activities, pain, discomfort, and anxiety/depression. Responses to each of the 5 health states are measured on a 3-point scale (level 1 = no problem; level 2 = some or moderate problem(s) and level 3 = unable, or extreme problems). Responses are typically converted into health utilities or valuations on a scale ranging from 0 (worst health) to 1 (perfect health). The thermometer score ranges from 0 (worst imaginable health state) to 100 (best imaginable health state). Changes from Baseline were analyzed by mixed model-repeated measures ANCOVA. A negative adjusted mean change from Baseline represents a worsening of quality of life.

  • Number of Participants With an Improvement in Eastern Cooperative Oncology Group (ECOG) Performance Status at the Indicated Time Points [ Time Frame: From randomization until the end of the study (up to 84 months) ] [ Designated as safety issue: No ]
    Improvement is defined as a decrease from Baseline by at least one step on the ECOG performance status scale (improvement categorized as yes or no). The proportion of participants with improvement was compared between treatment groups with the Cochran-Mantel-Haenszel test adjusting for stratification factors (response at entry, number of prior treatments and type of prior treatment). Improvement in ECOG performance status was measured at the available time points that have data: Cycle (C) 1 Week (W) 2/Month (M) 1, C2 W9/M3, C3 W17/M5, C4 W25/M7, C5 W33/M9, C6 W41/M11, C7 W49/M13, C8 W57/M15, C9 W65/M17, C10 W73/M19, C11 W81/M21, C12 W89/M23, C13 W97/M25, 3M Follow-up (FU), 6M FU, 9M FU, 12M FU, 15M FU, 18M FU, 21M FU and Withdrawal (WDL).

  • Number of Participants With the Indicated Constitutional or B-symptoms at the Indicated Time Points [ Time Frame: From Screening until the end of the study (up to 84 months) ] [ Designated as safety issue: No ]
    Par. with the indicated constitutional or B-symptoms (night sweats [without signs of infection]; unintentional weight loss >= 10% within the previous 6 months; recurrent, unexplained fever of > 38 degrees celcius or 100.5 degrees fahrenheit for 2 weeks; and extreme fatigue) were presented. The proportion of par. with no night sweats, no weight loss, no fever and no extreme fatigue were summarized and compared to the proportion of par. with >= 1 of the following: night sweats, weight loss, fever or extreme fatigue. The proportions were compared between treatment groups with the Cochran-Mantel-Haenszel test adjusting for stratification factors (response at entry, number of prior treatments and type of prior treatment). B-symptoms were assessed at the following time points: Screening, C1 W1/M1, C2 W9/M3, C3 W17/M5, C4 W25/M7, C5 W33/M9, C6 W41/M11, C7 W49/M13, C8 W57/M15, C9 W65/M17, C10 W73/M19, C11 W81/M21, C12 W89/M23, C13 W97/M25, 3M, 6M, 9M, 12M, 15M, 18M, 21M FU and WDL.

  • Number of Participants With Grade 3 and Above Adverse Event of Infection [ Time Frame: From first dose of study medication until 60 days after the last dose of study medication or until the last observation at Visit 14 (up to 84 months) ] [ Designated as safety issue: No ]
    Participants with Grade 3, Grade 4 and Grade 5 adverse event of infection are presented. Adverse events were graded according to the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) grade, version 4.0 (1=mild; 2=moderate; 3=severe; 4=life-threatening/disabling; 5=death).

  • Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) [ Time Frame: From first dose of study medication until 60 days after the last dose of study medication or until the last observation at Visit 14 (up to 24 months for non-serious AEs and 84 months for SAEs) ] [ Designated as safety issue: No ]
    An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed. Refer to the general Adverse AE/SAE module for a complete list of AEs and SAEs.

  • Number of Participants With a Grade 3 or Grade 4 Myelosuppression (Anemia, Neutropenia, or Thrombocytopenia) at Indicated Time Points [ Time Frame: From first dose of study medication until 60 days after the last dose of study medication or until the last observation at Visit 14 (up to 24 months) ] [ Designated as safety issue: No ]
    Myelosuppression is defined as the decrease in the ability of the bone marrow to produce blood cells. Number of participants who reported myelosuppression (anemia [low hemoglobin count], neutropenia [low neutrophil count], and thrombocytopenia [low platelet count]) are presented. AEs were graded according to NCI common terminology criteria for adverse events (CTCAE) grade, version 4.0 (1, mild; 2, moderate; 3, severe; 4, life-threatening/disabling; 5, death). Assessment was at the following time points: Screening, C1 W1/M1, C1 W2/M1, C2 W9/M3, C3 W17/M5, C4 W25/M7, C5 W33/M9, C5 unscheduled, C6 W41/M11, C6 unscheduled, C7 W49/M13, C8 W57/M15, C8 unscheduled, C9 W65/M17, C10 W73/M19, C11 W81/M21,C11 unscheduled, C12 W89/M23, C13 W97/M25, 3M, 6M, 9M, 12M FU and WDL.

  • Number of Participants Who Received at Least One Transfusion During the Study [ Time Frame: From randomization until the end of the study (up to 24 months) ] [ Designated as safety issue: No ]
    Participants who received at least one transfusion (any blood products or blood supportive care product) during the study are presented.

  • Number of Participants Diagnosed With Autoimmune Hemolytic Anemia (AIHA) [ Time Frame: From randomization until the end of the study (up to 24 months) ] [ Designated as safety issue: No ]
    AIHA is a disease where the body's immune system fails to recognize red blood cells as "self" and begins destroying these red blood cells. The number of participants diagnosed with AIHA are presented.

  • Number of Participants With Positive and Negative Human Anti-human Antibody (HAHA) at the Indicated Time Points [ Time Frame: Pre-dose (Visit 1), Months 7, 13, 19, and 25 during treatment and at 3 and 6 months after last ofatumumab dose (up to 30 months) ] [ Designated as safety issue: No ]
    HAHA are indicators of immunogenicity to ofatumumab. Blood samples were drawn from participants at Visit 1, Months 7, 13, 19, and 25 during treatment and at 3 and 6 months after last ofatumumab dose for analysis of HAHA. The presence of HAHA in human serum was determined using a validated electrochemiluminescent assay in a multi-tier assay format. All samples were first assessed in a screening (SCR) assay (A), and the potential positive (Pos) samples were further tested in the confirmation (CNF) assays. Confirmed positives were reported as HAHA positive and titer was determined for each positive sample. The drug tolerance of the HAHA assay is 200 microgram/milliliter (µg/mL); thus, samples that tested negative in the assay and had ofatumumab concentrations no more than 200 µg/mL were considered as conclusive negative (C Neg) results.

  • Mean Change From Baseline in the Immunoglobulin (Ig) Antibodies IgA, IgG, and IgM at Indicated Time Points [ Time Frame: Baseline, every six months during treatment, and after last treatment visit and/or upon relapse (up to 24 months) ] [ Designated as safety issue: No ]
    Immunoglobulins, or antibodies, are large proteins used by the immune system to identify and neutralize foreign particles such as bacteria and viruses. Their normal blood levels indicate proper immune status. Low levels indicate immuno-suppression. IgA, IgG, and IgM were measured in the blood samples of the participants. Baseline IgA, IgG, and IgM values are the last pre-dose assessment values performed on Cycle 1 Day 1. Change from Baseline was calculated as the post-baseline value minus the Baseline value. Immunoglobulins were measured at the following time points: Baseline (BL) and Cycle (C) 2 Week (W) 9/Month (M) 3, C3 W17/M5, C4 W25/M7, C5 W33/M9, C6 W41/M11, C7 W49/M13, C8 W57/M15, C9 W65/M17, C10 W73/M19, C11 W81/M21, C12 W89/M23, C13 W97/M25, 3M Follow-up (FU), 6M FU, 9M FU, 12M FU, 15M FU, 18M FU, 21M FU and Withdrawal (WDL) were presented.

  • Number of Participants Who Were Positive and Negative for Minimal Residual Disease (MRD) at Any Visit [ Time Frame: From randomization until the end of the study (up to 84 months) ] [ Designated as safety issue: No ]
    MRD refers to small number of leukemic cells that remain in the participant during treatment or after treatment at the time the participant achieved a confirmed complete remission. Number of participants who were positive and negative for minimal residual disease (MRD) at any visit is presented.

  • Change From Baseline in Cluster of Differentiation (CD) CD5+CD19+ and CD5-CD19+ Cell Counts at the Indicated Time Points [ Time Frame: Baseline and every two months from Month 3 until Month 25 and at every follow-up visit (up to 84 months) ] [ Designated as safety issue: No ]
    CD5+CD19+ cells were counted by flow cytometry. Flow cytometry is a technique for counting and examining microscopic particles with an electronic detection apparatus. Baseline CD5+CD19+ and CD5-CD19+ cell count value is the last pre-dose assessment values performed on Cycle 1 Day 1. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Flowcytometry was performed at the following time points: Cycle (C) 2 Week (W) 9/Month (M) 3, C3 W17/M5, C4 W25/M7, C5 W33/M9, C6 W41/M11, C7 W49/M13, C8 W57/M15, C9 W65/M17, C10 W73/M19, C11 W81/M21, C12 W89/M23, C13 W97/M25, 3M FOLLOW-UP (FU), 6M FU, 9M FU, 12M FU, 15M FU, 18M FU, 21M FU and Withdrawal (WDL) are presented.

  • Summary of Covariates to Compute Cox Proportional Hazards Regression Model for Relationship Between Investigator Assessed Progression-free Survival and the Indicated Prognostic Markers [ Time Frame: From Baseline until the end of the study (up to 84 months) ] [ Designated as safety issue: No ]
    Blood samples were collected for the assessment of the following prognostic markers at Baseline (BL) and upon relapse: immunoglobulin heavy chain variable region (IgVH) mutational status; VH3-21 usage; Cytogenetics (by fluorescent in situ hybridization [FISH]) including 6q-, 11q-, +12q, 17p-, 13q- deletions; beta 2 microglobulin. Cox-regression model was used to explore the relationship between progression-free survival and the following explanatory variables: treatment group, cytogenetics (analyzed by FISH) at BL, IgVH mutational status at BL, beta 2 microglobulin at BL, BL CD20 and BL complement level. For each covariate, a hazard ratio <1 indicates a lower risk on the first effect tested compared with the other effects tested. Cytogenetics Group (based on >=20%)=CY G.

  • Cmax and Ctrough of Ofatumumab [ Time Frame: Pre-dose, Day 1, Day 8, Months 3, 5, 7, 9, 13, 19 and 25; and at 3 and 6 months post last dose (up to 30 months) ] [ Designated as safety issue: No ]
    Blood samples were collected to assess the plasma concentration of ofatumumab. Maximum concentration (Cmax) and observed drug concentration prior to the next dose (Ctrough) were determined. Blood samples were collected at pre-dose and 0.5 hour (h) after the end of the infusion at treatment on Month 1 Week1 (Day 1), Month 1 Week 2 (Day 8), Months 3, 7, 13, 19 and 25. In addition, pre-dose samples were collected prior to ofatumumab administration on Months 5 and 9. Also, samples were collected at any time of day during clinic visits at 3 and 6 months post-last ofatumumab dose.

  • Total Plasma Clearance (CL) of Ofatumumab [ Time Frame: Pre-dose, Day 1, Day 8, Months 3, 5, 7, 9, 13, 19 and 25; and at 3 and 6 months post last dose (up to 30 months) ] [ Designated as safety issue: No ]
    Plasma clearance is defined as the plasma volume which is totally cleared of drug per unit of time. Blood samples were collected at pre-dose and 0.5 h after the end of the infusion at treatment on Month 1 Week1 (Day 1), Month 1 Week 2 (Day 8), Months 3, 7, 13, 19 and 25. In addition, pre-dose samples were collected prior to ofatumumab administration on Months 5 and 9. Also, samples were collected at any time of day during clinic visits at 3 and 6 months post-last ofatumumab dose.

  • AUC(0-tau) of Ofatumumab [ Time Frame: Pre-dose, Day 1, Day 8, Months 3, 5, 7, 9, 13, 19 and 25; and at 3 and 6 months post last dose (up to 30 months) ] [ Designated as safety issue: No ]
    Area under the concentration time curve over the dosing interval (AUC[0-tau]) is a measure of drug exposure over time. AUC(0-tau) is defined as the area under the ofatumumab plasma concentration-time curve from dosing to time tau, where tau is the length of the dosing interval of ofatumumab. For estimation of AUC(0-tau), blood samples were collected at pre-dose and 0.5 h after the end of the infusion at treatment on Month 1 Week1 (Day 1), Month 1 Week 2 (Day 8), Months 3, 7, 13, 19 and 25. In addition, pre-dose samples were collected prior to ofatumumab administration on Months 5 and 9. Also, samples were collected at any time of day during clinic visits at 3 and 6 months post-last ofatumumab dose.

  • Vss of Ofatumumab [ Time Frame: Pre-dose, Day 1, Day 8, Months 3, 5, 7, 9, 13, 19 and 25; and at 3 and 6 months post last dose (up to 30 months) ] [ Designated as safety issue: No ]
    Volume of distribution at steady state (Vss) is defined as the distribution of a drug between plasma and the rest of the body at steady state. Blood samples were collected at pre-dose and 0.5 h after the end of the infusion at treatment on Month 1 Week1 (Day 1), Month 1 Week 2 (Day 8), Months 3, 7, 13, 19 and 25. In addition, pre-dose samples were collected prior to ofatumumab administration on Months 5 and 9. Also, samples were collected at any time of day during clinic visits at 3 and 6 months post-last ofatumumab dose.

  • Plasma Half-life (t1/2) of Ofatumumab [ Time Frame: Pre-dose, Day 1, Day 8, Months 3, 5, 7, 9, 13, 19 and 25; and at 3 and 6 months post last dose (up to 30 months) ] [ Designated as safety issue: No ]
    The terminal half-life (t1/2) of ofatumumab is defined as the time required for the plasma concentration of ofatumumab to reach half of its original concentration. Blood samples were collected to assess the plasma half-life of ofatumumab. Blood samples were collected at pre-dose and 0.5 h after the end of the infusion at treatment on Month 1 Week1 (Day 1), Month 1 Week 2 (Day 8), Months 3, 7, 13, 19 and 25. In addition, pre-dose samples were collected prior to ofatumumab administration on Months 5 and 9. Also, samples were collected at any time of day during clinic visits at 3 and 6 months post-last ofatumumab dose.


Enrollment: 480
Study Start Date: May 2010
Estimated Study Completion Date: May 2017
Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ARM A: Ofatumumab
Ofatumumab Treatment: 300 mg IV Week 1 followed by 1000 mg IV Week 2 1000 mg IV (a dose every 8 weeks for up to 2 years following the first 1000 mg dose)
Biological: Ofatumumab
Ofatumumab for maintenance therapy as IV infusions every 8 weeks . The first dose will be 300 mg followed 1 week later by 1000 mg and 1000 mg every 8 weeks thereafter for up to 2 years).
ARM B: Observation and assessments as per Arm A
Disease status assessments to determine subject response or progression will be performed approximately every 8 weeks for up to 2 years for both arms according to IWCLL criteria
Other: Observation
Observation/Safety Evaluation

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adults with documented diagnosis of CLL based on the modified IWCLL updated NCI-WG guidelines (Hallek, 2008)
  • At least PR according to the revised 2008 NCI-WG CLL criteria, within 3 months of the response assessment after the last dose of 2nd/3rd line treatment
  • The anti-leukemic treatment before study entry should have been at least 3 months or 3 cycles
  • ECOG Performance Status of 0-2
  • Signed written informed consent prior to performing any study-specific procedures

Exclusion Criteria:

  • Known primary or secondary fludarabine-refractory subjects, defined as treatment failure (failure to achieve a CR or PR) or disease progression within 6 months
  • Prior maintenance therapy
  • Known transformation of CLL (eg.Richter's transformation), prolymphocytic leukemia (PLL), or CNS involvement of CLL
  • Active Autoimmune hemolytic anemia (AIHA) requiring treatment except if in the opinion of the investigator and medical monitor it is thought not to affect the subject's safety, the conduct of the study or the interpretation of the data
  • Previous autologous or allogeneic stem cell transplantation
  • Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment such as, but not limited to chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis and active Hepatitis B or C
  • Other past or current malignancy (with the exception of basal cell carcinoma or the skin or in situ carcinoma of the cervix or breasts) unless the tumor was successfully treated with curative intent at least 2 years prior to trial entry except if in the opinion of the investigator and medical monitor it is thought not to affect the subject's safety, the conduct of the study or the interpretation of the data
  • Clinically significant cardiac disease, including unstable angina, acute myocardial infarction within 6 months prior to screening, congestive heart failure, and arrhythmia requiring therapy, with the exception of exta systoles or minor conduction abnormalities except if in the opinion of the investigator and medical monitor it is thought not to affect the subject's safety, the conduct of the study or the interpretation of the data
  • History of significant cerebrovascular disease or event with symptoms or sequelae
  • Significant concurrent, uncontrolled medical condition that in the opinion of the investigator or GSK medical monitor contraindicates participation in this study
  • Other anti-leukemic use of medications including glucocorticoids
  • Known HIV positive
  • Screening laboratory values: platelets <50 x 109/L, neutrophils<1.0 x 109/L, Creatinine > 1.5 X upper normal limit (unless normal creatinine clearance), total bilirubin >1.5 X upper normal limit, ALT >2.5 X upper normal limit (unless due to liver involvement of CLL), alkaline phosphase > 2.5 X upper normal limit
  • Known or suspected hypersensitivity to ofatumumab that in the opinion of the investigator or medical monitor contraindicates study participation
  • Subjects who have received treatment with any non-marketed drug substance or experimental therapy within 5-terminal half-lives or 4 weeks whichever is longer prior to first dose of study medication or currently participating in any other interventional clinical study Note: Participation in any other interventional clinical study after disease progression during post PD follow-up is permitted
  • Lactating women, women with a positive pregnancy test at Visit 1 or women (of childbearing potential) as well as men with partners of childbearing potential, who are not willing to use adequate contraception from study start through one year following last ofatumumab dose. Adequate contraception is defined as abstinence, oral hormonal birth control, implants of levonorgestrel, estrogenic vaginal ring, percutaneous contraceptive patches, intrauterine device, and male partner sterilization if male partner is sole partner for that subject. For females in the USA, the use of a double barrier method is also considered adequate (condom or occlusive cap plus spermicidal agent).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01039376

  Show 203 Study Locations
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT01039376     History of Changes
Other Study ID Numbers: 112517
Study First Received: December 23, 2009
Results First Received: February 12, 2015
Last Updated: April 2, 2015
Health Authority: United States: Institutional Review Board
United States: Food and Drug Administration

Keywords provided by GlaxoSmithKline:
ofatumumab
maintenance therapy
anti-CD20 monoclonal antibody

Additional relevant MeSH terms:
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Lymphoid
Immune System Diseases
Immunoproliferative Disorders
Leukemia
Leukemia, B-Cell
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type

ClinicalTrials.gov processed this record on July 28, 2015